Scientists at Israel’s Weizmann Institute have been able to silence the gene controlling the p53 protein known as “the guardian of the genome”. The p53 protein is mutated or dysfunctional in over two-thirds of all cancers. Korean biotech BioLeaders is investing $10 million in the new Israeli therapy.
https://wis-wander.weizmann.ac.il/life-sciences/switching-sides-betrayal-anti-cancer-gene